CDMO Model
Rethinking the Conventional CDMO Model
Wheeler Bio
PAO-08-24-CL-04Jul 29, 2024
The PHASE Platform
How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success
Wheeler Bio
PAO-05-24-CL-01May 08, 2024
Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC
Wheeler Bio
PR-M11-23-01Nov 08, 2023
Series A Funding
Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma
Wheeler Bio
PR-M10-22-02Oct 05, 2022
Leadership
Wheeler Bio Announces Roger Lias, Ph.D. as President and Chief Operating Officer
Wheeler Bio
PR-M09-22-05Sep 22, 2022
Cell Line Development
Integrating Cell Line and CMC Development
Stephen Hamilton, Ph.D.; Mike Brem
Wheeler Bio
PAO-06-022-CL-12Sep 02, 2022
Oncology Collaboration
Tegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor Treatment
Tegmine Therapeutics
PR-M04-22-03Apr 06, 2022
Financing
Wheeler Bio Announces $14M Seed Round To Expand Access To Portable CMC™
Wheeler Bio
PR-M01-22-01Jan 04, 2022